Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + docetaxel + prednisone
- Development stage
- Unknown
- Lead developer
- New Mexico Cancer Research Alliance
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy involves the addition of the biguanide metformin to the standard-of-care regimen of docetaxel and prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Metformin, primarily used as an antihyperglycemic agent for type 2 diabetes, is investigated in oncology for its ability to activate AMP-activated protein kinase (AMPK), which subsequently inhibits the mTOR pathway and reduces circulating insulin and insulin-like growth factor 1 (IGF-1) levels—factors often associated with tumor progression. Docetaxel is a taxane chemotherapy agent that stabilizes microtubules, thereby inhibiting mitotic cell division and inducing apoptosis. Prednisone is a corticosteroid administered to mitigate the side effects of docetaxel and provide secondary hormonal therapy benefits. The New Mexico Cancer Research Alliance conducted a Phase II trial to evaluate whether this combination improves clinical outcomes and manages toxicity in patients with endocrine-resistant prostate cancer.
- Other names
- Metformin with Docetaxel and PrednisoneMetformin hydrochloride + Docetaxel + Prednisone
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)mTOR (Mammalian target of rapamycin kinase)GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on metformin + docetaxel + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + docetaxel + prednisone.